Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma | Zendy

Eliezer M. Van Allen | Zendy; Vivian Wai Yan Lui | Zendy; Ann Marie Egloff | Zendy; Eva M. Goetz | Zendy; Hua Li | Zendy; Jonas T. Johnson | Zendy; Umamaheswar Duvvuri | Zendy; Julie E. Bauman | Zendy; Nicolas Stransky | Zendy; Yan Zeng | Zendy; Breean R. Gilbert | Zendy; Kelsey P. Pendleton | Zendy; Lin Wang | Zendy; Simion I. Chiosea | Zendy; Carrie Sougnez | Zendy; Nikhil Wagle | Zendy; Fan Zhang | Zendy; Yu Du | Zendy; David A. Close | Zendy; Paul A. Johnston | Zendy; Aaron McKenna | Zendy; Scott L. Carter | Zendy; Todd R. Golub | Zendy; Gad Getz | Zendy; Gordon B. Mills | Zendy; Levi A. Garraway | Zendy; Jennifer R. Grandis | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma

Author(s) -

Eliezer M. Van Allen,

Vivian Wai Yan Lui,

Ann Marie Egloff,

Eva M. Goetz,

Hua Li,

Jonas T. Johnson,

Umamaheswar Duvvuri,

Julie E. Bauman,

Nicolas Stransky,

Yan Zeng,

Breean R. Gilbert,

Kelsey P. Pendleton,

Lin Wang,

Simion I. Chiosea,

Carrie Sougnez,

Nikhil Wagle,

Fan Zhang,

Yu Du,

David A. Close,

Paul A. Johnston,

Aaron McKenna,

Scott L. Carter,

Todd R. Golub,

Gad Getz,

Gordon B. Mills,

Levi A. Garraway,

Jennifer R. Grandis

Publication year - 2015

Publication title -

jama oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 8.846

H-Index - 99

eISSN - 2374-2445

pISSN - 2374-2437

DOI - 10.1001/jamaoncol.2015.34

Subject(s) - erlotinib , medicine , head and neck squamous cell carcinoma , erlotinib hydrochloride , epidermal growth factor receptor , oncology , lung cancer , cancer , head and neck cancer , cancer research

Randomized clinical trials demonstrate no benefit for epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in unselected patients with head and neck squamous cell carcinoma (HNSCC). However, a patient with stage IVA HNSCC received 13 days of neoadjuvant erlotinib and experienced a near-complete histologic response.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research